Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text

Medicine, Gynecology, Oncology +14

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

Medicine, Gynecology, Oncology +11

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

Andreas du Bois · JNCI Journal of the National Cancer Institute · 2003 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +17

A Confidence Interval for the Median Survival Time

Ron Brookmeyer, John Crowley · Biometrics · 1982 · 908 citations

Public Health, Biostatistics, Clinical Epidemiology +16